|
|
||||||||
From the Departments of Neuroradiology (Drs. Küker and Nägele) and Neurology (Drs. Weller and Herrlinger), Medical School, University of Tübingen; Department of Hematology and Oncology (Dr. Thiel), University Hospital Benjamin Franklin, Berlin, Germany; and Department of Neuroradiology (Dr. Küker), The Radcliffe Infirmary, Oxford, UK.
Address correspondence and reprint requests to Dr. Wilhelm Küker, Department of Neuroradiology, The Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK; e-mail: wilhelm.kueker{at}orh.nhs.uk
The authors investigated the applicability of Macdonald response criteria to patients with primary CNS lymphoma (PCNSL). Four of 68 patients with persisting contrast-enhancing lesions after primary therapy did not receive further therapy, and none showed tumor progression after up to 54 months. Because contrast enhancement may not necessarily indicate residual, biologically active lymphoma, the authors propose a modification of the Macdonald response criteria.
Disclosure: The authors report no conflicts of interest.
Received May 16, 2005. Accepted in final form June 16, 2005.
This article has been cited by other articles:
![]() |
U. Schlegel, A. Jurgens, H. Pels, W . Kuker, and U. Herrlinger Primary central nervous system lymphomas (PCNSL): MRI response criteria revised Neurology, April 25, 2006; 66(8): 1287 - 1287. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |